Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis.
about
Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes.
P2860
Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 March 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Patient-reported outcomes from ...... fractory rheumatoid arthritis.
@en
Patient-reported outcomes from ...... fractory rheumatoid arthritis.
@en-gb
Patient-reported outcomes from ...... fractory rheumatoid arthritis.
@nl
type
label
Patient-reported outcomes from ...... fractory rheumatoid arthritis.
@en
Patient-reported outcomes from ...... fractory rheumatoid arthritis.
@en-gb
Patient-reported outcomes from ...... fractory rheumatoid arthritis.
@nl
prefLabel
Patient-reported outcomes from ...... fractory rheumatoid arthritis.
@en
Patient-reported outcomes from ...... fractory rheumatoid arthritis.
@en-gb
Patient-reported outcomes from ...... fractory rheumatoid arthritis.
@nl
P2093
P2860
P1154
2-s2.0-85016139591
P1433
P1476
Patient-reported outcomes from ...... fractory rheumatoid arthritis.
@en
P2093
Amy M DeLozier
Carol L Gaich
Cecile Hsiao-Chun Chang
Jiajun Liu
Jose Maldonado Cocco
Ricardo Blanco
Stephanie de Bono
Terence Rooney
Ying-Chou Chen
P2860
P304
P356
10.1136/RMDOPEN-2016-000410
P577
2017-03-21T00:00:00Z
P6179
1084225732